This literature review addresses the questions of the use of lamotrigine at different ages: during the pubertal period, in women of fertile age, during pregnancy, during breast feeding, and during the climacteric period. Particular attention is paid to the low teratogenic potential of lamotrigine used as monotherapy. It is concluded that lamotrigine is appropriate for use in partial and generalized epilepsy in women.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
P. N. Vlasov, M. V. Antonyuk, N. V. Orekhova, et al., Zh. Nevrol. Psikhiat., Epilepsy Supplement, No. 3, 47–51 (2008).
P. N. Vlasov “Clinical pharmacology of medicines using in convulsive syndrome,” in: Clinical Pharmacology. National Guidelines [in Russian], GEOTAR-Media, Moscow (2009), Chapter 29, 882 (addendum on compact disk).
E. V. Zheleznova, “Treatment with antieptileptic agents and its influence on reproductive and mental functions in epilepsy in women,” Atmosf. Nervn. Bolezni, No. 1, 28–32 (2010).
L. R. Zenkov, “Hypersexuality as a side effect of lamotrigine. Description of a case and review of the literature,” Neurol. Zh., No. 4 27–31 (2009).
V. A. Karlov (ed.) and P. N. Vlasov, “Epilepsy in women,” in: Epilepsy in Children and Adults, Women and Men [in Russian], Meditsina, Moscow (2010), Chapter 32, pp. 527–567.
EURAP. An International Antiepileptic Drugs and Pregnancy Register, Interim report (2010).
T. Glauser, E. Ben-Menachem, B. Bourgois, et al., “ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes,” Epilepsia, 47, 1094–1120 (2006).
C. L. Harden, K. J. Meador, P. B. Pennell, et al., “Management issues for women with epilepsy – Focus on pregnancy (an evidence-based review). II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society,” Epilepsia, 50, 1237–1246 (2009).
C. L. Harden, P. B. Pennell, B. S. Koppel, et al., “Management issues for women with epilepsy – Focus on pregnancy (an evidence-based review). III. Vitamin K, folic acid, blood levels, and breast-feeing: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society,” Epilepsia, 50, 1247–1255 (2009).
S. Karceski, M. Morrell, and D. Carpenter, “Treatment of epilepsy in adults: expert opinion,” Epilepsy Behavior, 7, Suppl. 1, S1–S64 (2005).
Lamotrigine Pregnancy Registry (EPI40048), Final report (Sept. 1, 1992 – March 31, 2010) (2010).
A. G. Marson, A. M. Al-Kharusi, M. Alwaidh, et al., “The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial,” Lancet, 369, 1000–1015 (2007).
G. Montouris and B. Abou-Khalil, “The first line of therapy in a girl with juvenile myoclonic epilepsy: Should it be valproate or a new agent?” Epilepsia, 50, Suppl. 8, 16–20 (2009).
M. J. Morrell, J. Isojiirvi, A. E. Taylor, et al., “Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy,” Epilepsy Res., 54, No. 2–3, 190–199 (2003).
J. Morrow, A. Russell, E. Guthrie, et al., “Malformation risks of antiepileptic drugs in pregnancy: prospective study from the UK epilepsy and pregnancy register,” J. Neurol. Neurosurg. Psychiat., 77, 193–198 (2006).
A. M. Pack, M. J. Morrell, R. Marcus, et al., “Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy,” Ann. Neurol., 57, 252–257 (2005).
A. Pack, “Bone health in people with epilepsy: is it impaired and what are the risk factors?” Seizure, 17, 181–186 (2008).
A. Sabers, J. M. Bucholt, P. Uldall, and E. L. Hanson, “Lamotrigine plasma levels reduced by oral contraceptives,” Epilepsy Res., 47, 151–154 (2001).
The Epilepsies: the Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care, NICE: Clinical Guideline 20, London (2004).
T. A. Tran, I. E. Leppik, K. Blesi, et al., “Lamotrigine clearance during pregnancy,” Neurology, 59, 251–255 (2002).
I. Valencia, G. Pinot-Ripoll, D. S. Khurana, et al., “Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy,” Eur. J. Paediat. Neurol., 13, 141–145 (2009).
J. W. Wheless, D. F. Clarke, A. Arzimanoglou, and D. Carpenter, “Treatment of pediatric epilepsy: European expert opinion 2007,” Epileptic Disord., 9, No. 4, 353–412 (2007).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 111, No. 5, Iss. 2, Epilepsy, pp. 38–42, May, 2011.
Rights and permissions
About this article
Cite this article
Vlasov, P.N., Dranko, D.V. & Agranovich, O.V. Lamotrigine in the Treatment of Epilepsy in Women. Neurosci Behav Physi 42, 969–972 (2012). https://doi.org/10.1007/s11055-012-9664-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-012-9664-1